US 12,029,786 B2
Composition and method of mRNA vaccines against novel coronavirus infection
Shenggao Tang, Guangzhou (CN); Dong Shen, Baltimore, MD (US); Chun Lu, Montreal (CA); Ziyang He, Potomac, MD (US); Jiaxi He, Baltimore, MD (US); and Patrick Y. Lu, Potomac, MD (US)
Assigned to RNAimmune, Inc., Germantown, MD (US)
Filed by RNAimmune, Inc., Gaithersburg, MD (US)
Filed on Feb. 8, 2021, as Appl. No. 17/170,876.
Claims priority of provisional application 63/130,581, filed on Dec. 24, 2020.
Claims priority of provisional application 63/058,463, filed on Jul. 29, 2020.
Claims priority of provisional application 62/971,834, filed on Feb. 7, 2020.
Prior Publication US 2022/0040292 A1, Feb. 10, 2022
Int. Cl. A61K 39/215 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61M 11/00 (2006.01)
CPC A61K 39/215 (2013.01) [A61K 9/0019 (2013.01); A61K 9/5123 (2013.01); A61P 31/14 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/544 (2013.01); A61K 2039/55555 (2013.01); A61M 11/00 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/20071 (2013.01)] 19 Claims
 
1. A composition comprising an effective amount of a messenger ribonucleic acid (mRNA) that comprises an open reading frame (ORF) encoding a 2019-nCoV protein or protein fragment formulated in a pharmaceutically acceptable carrier, wherein said mRNA and said carrier form a polymeric nanoparticle and wherein the 2019-nCoV protein or protein fragment is encoded by SEQ ID NO: 89.